About the Company
Ramon Martin Chavez (born c. 1964) is an American investment banker and entrepreneur. He is vice chairman and partner of Sixth Street Partners. Previously, he served in a variety of senior roles at Goldman Sachs, including chief information officer (2014–2017), chief financial officer, and global co-head of the firm's Securities Division. Marty was also a partner and member of Goldman's management committee. He was the chief technology officer and co-founder of Quorum Software Systems and CEO and co-founder of Kiodex. He is chairman of the board of computational pharmaceutical company Recursion, Board Observer of biotech company Earli and longevity biopharma company Cambrian Biopharma, and board member of Alphabet Inc. Chavez was appointed president of Harvard University's board of overseers for the 2020–21 academic year.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RXRX News
Recursion Pharmaceuticals Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares
Blake Borgeson, Director of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 11,447 shares of the company. The transaction ...
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion Pharmaceuticals' market cap currently stands ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner ...
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Recursion strengthened its tech stack through partnerships and collaborations with big players. Read why I will remain on the ...
Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE ...
Is Recursion Pharmaceuticals Inc Stock Good For Long-Term Investing?
Coming back to Recursion Pharmaceuticals Inc (NASDAQ:RXRX), we note that the average 3-month trading volume was 7.17 million, while that of the preceding 10-day period stands at 4.97 million. Current ...
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares
Recursion Pharmaceuticals Inc (NASDAQ:RXRX), a biotechnology company that utilizes an AI-powered platform to discover drugs that can potentially treat rare genetic diseases and other conditions ...
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares
Recursion Pharmaceuticals Inc (NASDAQ:RXRX), a biotechnology company that utilizes an AI-powered platform to discover drugs that can potentially treat rare genetic diseases and other conditions, has ...
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares
Recursion Pharmaceuticals Inc (NASDAQ:RXRX), a biotechnology company that utilizes an AI-powered platform to discover drugs that can potentially treat rare genetic diseases and other conditions, has ...
Loading the latest forecasts...